Cargando…

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin lymphoma, including diffuse large B-cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hicks, Stuart W., Lai, Katharine C., Gavrilescu, L. Cristina, Yi, Yong, Sikka, Surina, Shah, Prerak, Kelly, Meghan E., Lee, Jenny, Lanieri, Leanne, Ponte, Jose F., Sloss, Callum M., Romanelli, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540712/ https://www.ncbi.nlm.nih.gov/pubmed/28753442 http://dx.doi.org/10.1016/j.neo.2017.06.001

Ejemplares similares

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
por: Beckwith, Kyle A., et al.
Publicado: (2014)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models()
por: Ponte, Jose F., et al.
Publicado: (2016)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
por: Stathis, Anastasios, et al.
Publicado: (2018)

PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN
por: Pemmaraju, N., et al.
Publicado: (2022)

PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Daver, Naval, et al.
Publicado: (2023)

S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
por: Pemmaraju, Naveen, et al.
Publicado: (2023)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
por: Shah, Manisha H., et al.
Publicado: (2016)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
por: Fozza, Claudio, et al.
Publicado: (2011)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
por: Mohammed, Raihan, et al.
Publicado: (2019)

Trio sonatas, BWV 528, 529 and 530
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1993)

The truth about maximizing college 529 accounts
por: O'Shaughnessy, Lynn
Publicado: (2011)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness
por: Badin, Firas, et al.
Publicado: (2010)

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
por: Wei, Kai-Che, et al.
Publicado: (2018)

SAT-529 Practice Patterns in the Treatment of Male Osteoporosis
por: Choksi, Palak, et al.
Publicado: (2019)

ODP529 Update on the Prevalence and Pathogenesis of Central Hypothyroidism
por: Heshmati, Hassan M, et al.
Publicado: (2022)

THU529 Challenges In The Management Of Biochemically Silent Paraganglioma
por: Dewan, Sandesh, et al.
Publicado: (2023)

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20
por: Winiarska, Magdalena, et al.
Publicado: (2008)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities
por: Xu, Youzhi, et al.
Publicado: (2015)

Antitumor effectiveness of different amounts of electrical charge in Ehrlich and fibrosarcoma Sa-37 tumors
por: Ciria, HC, et al.
Publicado: (2004)

Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression
por: Yan, Xiaofei, et al.
Publicado: (2017)

Antitumor effect of TW-37, a BH3 mimetic in human oral cancer
por: Ahn, Chi-Hyun, et al.
Publicado: (2019)

Surgical Resection of Lung Metastases: Results from 529 Patients
por: Younes, Riad N., et al.
Publicado: (2009)

529 Prevalence of Bronchitis and Revealing of the Risk Factors in the Children's Population
por: Adamia, Nino, et al.
Publicado: (2012)

529. Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel
por: Arora, Vaneet, et al.
Publicado: (2018)

SAT529 An Uncommon Case Report Of A Paraaortic Paraganglioma
por: Askar, Esraa, et al.
Publicado: (2023)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
por: Keefer, Kimberly, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_edoet0ot1b2st1tr1nq77ei8kb